3SWAINSTON HT, PERRY CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder[J]. Drugs, 2004, 64(15): 1715-1736.
4SHI XJ, GENG F, JIAO Z, et al. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmaco- kinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis[J]. J Clin Pharm Ther, 2011, 36(5): 614-624.
5LIU YT, HAO HP, LIU CX, et ol. Drugs as CYP3A probes inducers, and inhibitors[J]. Drug Metab Rev, 2007, 39(4): 699 721.
6DALY AK. Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects[J]. Adv Pharmacol, 2012, 63 : 137-167.
7HU YF , TU JH , TAN ZR, et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects[J]. Xenobiotica, 2007, 37(3): 315-327.
8KUBO M, KOUE T, MAUNE H, et ol. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers : influence of CYP2D6 polymor- phism[J]. Drug Metab Pharmacokinet, 2007, 22(5): 358-366.
9Venkatakrishnan K, Von Moltke L L, Greenblatt D J. Human drug me- tabolism and the cytochromes P450: application and relevance of invitro models[ J]. J Clin Pharmacol,2001,41 (11) :1149-1179.
10Wang R W, Newton D J,Scheri T D,et aL Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N- demethylation. Competition during catalysis [ J ]. Drug Metal) Dispos, 1997,25(4) :502-507.
